Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib versus first-line injectable therapies in relapsing-remitting multiple sclerosis after unsatisfactory response
2012-003735-32Phase 3Withdrawn
- Sponsor
- AB Science
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of masitinib in multiple sclerosis (MS) (2 arms), sponsored by AB Science. Primary endpoint: Annualized relapse rate. Planned start Apr 2015; status: withdrawn.
02
Drugs
masitinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2012-003735-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003735-32.